These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 3093918)

  • 21. No effect of transfer factor in juvenile rheumatoid arthritis by double-blind trial.
    Høyeraal HM; Frøland SS; Salvesen CF; Munthe E; Natvig JB; Kåss E; Blichfeldt P; Hegna TM; Revlem E; Sandstad B; Hjort NL
    Ann Rheum Dis; 1978 Apr; 37(2):175-9. PubMed ID: 348131
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical trial of natural alpha interferon in multiple sclerosis.
    Knobler RL; Panitch HS; Braheny SL; Sipe JC; Rice GP; Huddlestone JR; Francis GS; Hooper CJ; Kamin-Lewis RM; Johnson KP
    Ann N Y Acad Sci; 1984; 436():382-8. PubMed ID: 6398020
    [No Abstract]   [Full Text] [Related]  

  • 23. A single-center, randomized, double-blind, placebo-controlled study of interferon beta-1b on primary progressive and transitional multiple sclerosis.
    Montalban X; Sastre-Garriga J; Tintoré M; Brieva L; Aymerich FX; Río J; Porcel J; Borràs C; Nos C; Rovira A
    Mult Scler; 2009 Oct; 15(10):1195-205. PubMed ID: 19797261
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Double-blind trial of the use of transfer factor in the treatment of Crohn's disease.
    Vicary FR; Chambers JD; Dhillon P
    Gut; 1979 May; 20(5):408-13. PubMed ID: 381124
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Letter: Transfer factor in multiple sclerosis.
    Behan PO
    Lancet; 1976 Jul; 2(7979):258. PubMed ID: 59273
    [No Abstract]   [Full Text] [Related]  

  • 26. [Treatment of patients with multiple sclerosis with transfer factor (author's transl)].
    Romano EL; Pulido M; Layrisse Z; Malavé I
    Acta Cient Venez; 1978; 29(1):49-52. PubMed ID: 757718
    [No Abstract]   [Full Text] [Related]  

  • 27. Therapeutic effect of vitamin D3 in multiple sclerosis patients.
    Mosayebi G; Ghazavi A; Ghasami K; Jand Y; Kokhaei P
    Immunol Invest; 2011; 40(6):627-39. PubMed ID: 21542721
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A double-blind controlled trial of high dose methylprednisolone in patients with multiple sclerosis: 1. Clinical effects.
    Milligan NM; Newcombe R; Compston DA
    J Neurol Neurosurg Psychiatry; 1987 May; 50(5):511-6. PubMed ID: 3295122
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A symposium on multiple sclerosis: management of MS.
    Kelly R
    Nurs Mirror Midwives J; 1976 Aug; 143(6):48-50. PubMed ID: 60750
    [No Abstract]   [Full Text] [Related]  

  • 30. Chronic systemic high-dose recombinant interferon alfa-2a reduces exacerbation rate, MRI signs of disease activity, and lymphocyte interferon gamma production in relapsing-remitting multiple sclerosis.
    Durelli L; Bongioanni MR; Cavallo R; Ferrero B; Ferri R; Ferrio MF; Bradac GB; Riva A; Vai S; Geuna M
    Neurology; 1994 Mar; 44(3 Pt 1):406-13. PubMed ID: 8145906
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evoked potentials predict the clinical changes in a multiple sclerosis drug study.
    Nuwer MR; Packwood JW; Myers LW; Ellison GW
    Neurology; 1987 Nov; 37(11):1754-61. PubMed ID: 3313101
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).
    Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH
    Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial.
    Torkildsen O; Wergeland S; Bakke S; Beiske AG; Bjerve KS; Hovdal H; Midgard R; Lilleås F; Pedersen T; Bjørnarå B; Dalene F; Kleveland G; Schepel J; Olsen IC; Myhr KM
    Arch Neurol; 2012 Aug; 69(8):1044-51. PubMed ID: 22507886
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group.
    Lancet; 1988 Jul; 2(8604):179-83. PubMed ID: 2899660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transfer factor. General aspects.
    Grob PJ
    Acta Neurol Scand Suppl; 1977; 63():217-26. PubMed ID: 322440
    [No Abstract]   [Full Text] [Related]  

  • 36. Evoked potentials in multiple sclerosis before and after high-dose methylprednisolone infusion.
    Smith T; Zeeberg I; Sjö O
    Eur Neurol; 1986; 25(1):67-73. PubMed ID: 3940867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hyperbaric oxygen therapy in chronic stable multiple sclerosis: double-blind study.
    Harpur GD; Suke R; Bass BH; Bass MJ; Bull SB; Reese L; Noseworthy JH; Rice GP; Ebers GC
    Neurology; 1986 Jul; 36(7):988-91. PubMed ID: 3520382
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hyperbaric oxygen and multiple sclerosis: final results of a placebo-controlled, double-blind trial.
    Barnes MP; Bates D; Cartlidge NE; French JM; Shaw DA
    J Neurol Neurosurg Psychiatry; 1987 Nov; 50(11):1402-6. PubMed ID: 3320274
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Linoleic acid and multiple sclerosis: a reanalysis of three double-blind trials.
    Dworkin RH; Bates D; Millar JH; Paty DW
    Neurology; 1984 Nov; 34(11):1441-5. PubMed ID: 6387534
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Transfer factor treatment of multiple sclerosis. A pilot study.
    Jersild C; Platz P; Svejgaard A; Pedersen L; Kam-Hansen S; Raun N; Mellerup E; Jacobsen B; Linnemann F; Westh P
    Acta Neurol Scand Suppl; 1977; 63():253-64. PubMed ID: 322441
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.